All Episodes

The Multidisciplinary Team: Your Guide to Cirrhosis and Portal Hypertension Care

Wilson Disease: Therapeutic Landscape & Future Directions

What You May Be Missing: Screening For Wilson Disease in Routine Clinical Practice

Complications of Cirrhosis: The Basics

TIPS Procedure: Identifying Candidates and Minimizing Risk

Timing Is Everything: When is TIPS Appropriate?

How to Monitor Patients With Compensated Cirrhosis

Management of Portal Hypertension

Navigating Treatment Options in 2026

Best Practices in Ongoing Monitoring of MASH Patients

Monitoring & Follow Up of Patients With CHB

What Are the Current Strategies for Managing Pruritus in Patients With PBC?

What Special Considerations Should Be Taken While Managing PBC in Pregnant Patients?

Pathophysiology and Overview of Hepatitis B

Patient Centric Care Approaches in CHB

Patient Centric Care Approaches in PBC

Education & Engagement for CHB Patients

Introduction to Understanding Hepatitis B

Quantitative HBsAg Testing in CHB Patients

Monitoring and Follow Up of Patients With PBC

Guideline Implementation for PBC Patients

Diet and Lifestyle Modifications in PBC: What Can We Recommend to Our Patients?

The Psychological Impact of PBC: Addressing Mental Health in Our Patients

How Can We Overcome Barriers to Treatment Adherence in PBC?

New Therapeutic Options and Management Strategies Symposium Recap

Managing Complications in PBC: How Do We Improve Patient Quality of Life?

New Treatment Options for PBC: What’s on the Horizon for Our Patients?

Physician Insights in Caring For Patients With PBC

Practical Approaches to PBC Clinical Management

Symptom Management in PBC Patients

PBC Patient Quality of Life

Preventing Clinical Decompensation in Cirrhosis and Portal Hypertension

Resmetirom: The First FDA-Approved Therapy for MASH

What is Resmetirom and How Does it Work to Treat MASH?

A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature

What is the Clinical Profile of Resmetirom, Including Dosing Schedules

Why is it Difficult to Predict Who Will Progress With MASH and How Quickly?

Talk About Role & Efficacy in Resmetirom: Elaborate on Response Rate

How Does MASH Progress Over Time?

Need for Clinicians to Better Understand The "Area Under the Curve" in Non-Response to UDCA

Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively

Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically

Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression

Not Responding to UDCA in the First Few Months, Need to Move on to Second-Line Therapy

Need for Earlier Evaluation of UDCA Response, Need for Earlier Consideration of Second-Line Therapy

Building a Sense of Urgency for PBC Patient Evaluation/Monitoring

Importance of Understanding Impact on Disease Outcomes: Progression to Fibrosis and Cirrhosis

Part 4- Cirrhosis and HE Patient Education

Part 3- HE Stratification and Surgery

Part 2- Refractory HE

Part 1- Initial Diagnosis Counseling of HE Patients

Key Take Aways-Major Advancements In The Management of MASH with Parvez, Mantry, MD

Metabolic-Associated Steatotic Liver Disease: Positioning New and Emerging Therapies with Nancy Reau, MD, Kimberly Brown, MD, and Steven Flamm, MD.

Health-Related Quality of Life and Emerging Therapies In PBC

CLDF Conversations - Host Nadege Gunn, MD Interview with Sujit Janardhan, MD, PhD

CLDF Conversations - Host Nancy Reau, MD with Special Guests Andrew S. DeLemos, MD & Chathur Acharya, MD

MASH- What We Don't Know, What We Want to Know

Strategies for Educating the APP Community on MASH

Using NITs to Identify and Manage MASH Patients

Incorporating the Newly Approved Therapy for MASH into Practice